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Enterovirus 71 (EV71) causes life-threatening disease 
outbreaks in young children in Asia. This cohort study was 
conducted to understand the dynamics of maternal EV71 
antibodies in Taiwanese young infants. Approximately 50% 
of neonates had detectable EV71 neutralizing antibodies, 
which declined to almost undetectable levels by 6 months 
of age.
T
ransplacental maternal antibodies protect young infants 
from infectious diseases. On the other hand, maternal 
antibodies in young infants may impede vaccine effective-
ness and confound interpretation of vaccine-induced im-
mune responses. Thus, a need exists to understand the dy-
namics of pathogen-speciﬁ  c maternal antibodies in young 
infants (1–3).
Enterovirus 71 (EV71) was ﬁ  rst isolated in California, 
USA, in 1969. Since then, EV71 has been isolated globally 
and causes life-threatening outbreaks in young children in 
Asia (4–10). National surveillance data and epidemiologic 
studies show that infants have an increased risk of severe 
EV71 infections in Taiwan (6–11). Consequently, vaccine 
development for EV71 in Taiwan should target infants. 
This cohort study was conducted to understand the dynam-
ics of EV71-speciﬁ  c maternal antibodies in young infants 
in Taiwan.
The Study
Seropositive rates of EV71 neutralizing antibodies in 
preschool children have been found to be higher in rural 
areas than in urban areas in Taiwan (11). We chose Chang 
Gung Memorial Hospital (CGMH) as a study site because 
it has large obstetric and pediatric populations and serves 
residents from rural and urban areas in northern Taiwan 
(7). Pregnant women having prenatal examinations at 
CGMH were invited to participate in the study. Serum 
samples were obtained from participating pregnant women 
and their children to measure EV71 neutralizing antibody 
titers immediately before delivery for pregnant women; at 
birth for neonates (cord blood); and at 6, 12, 24, 36, and 48 
months of age for infants. Institutional review board ap-
provals were obtained from CGMH and from the National 
Health Research Institutes, according to the Helsinki Dec-
laration. Informed consent was obtained from all mothers 
of participating infants. This report addresses the dynamics 
of EV71 maternal antibodies in young infants by 6 months 
of age.
Laboratory methods for measuring EV71 serum neu-
tralizing antibody titers followed standard protocols (7) 
and used a local strain (TW/E59/2002 [B4 genotype]) and 
rhabdomyosarcoma cells. Serial serum samples obtained 
from each pregnant woman and her infant were tested in 
the same run to reduce assay variations. The starting dilu-
tion was 1:8, and the cutoff level for seropositivity was 8. 
Undetectable titer was assigned a level of 2 for calculation 
of geometric mean titer (GMT). For determining serostatus 
(positive or negative), serum samples were tested only at 
1:8.
Under the assumption that levels of maternal antibod-
ies decline exponentially and constantly, this study used 
paired serum samples collected at birth and at 6 months 
of age to estimate the biological half-life that represents 
an overall half-life and that is crucial for interpreting anti-
body responses in young infants. Longitudinal and cross-
sectional methods of data analysis were used to estimate 
the biological half-life of pathogen-speciﬁ  c maternal anti-
bodies (1).
Obtaining monthly serum samples from young infants 
to measure seroprevalence of maternal EV71-speciﬁ  c anti-
bodies is unrealistic. Alternatively, the seroprevalence can 
be predicted mathematically. As has been shown in other 
viral pathogens, maternal antibody titers are assumed to 
follow a normal distribution after natural logarithm trans-
formation and to experience a constant exponential decay 
over time after an infant’s birth (1,12). If we assume nor-
mal distribution, 4 parameters (initial GMT at age i, SD of 
the distribution of antibody titers, decay rates of antibody 
titers, and cut-off for seropositivity) are crucial for estimat-
ing the seroprevalence in different ages (12).
Neutralization antibody titers were log-transformed to 
calculate the GMT and 95% conﬁ  dence intervals. Statis-
tical association between 2 nominal or ordinary variables 
was tested by using the χ2 test, McNemar test, Fisher exact 
test, or Mantel-Haenszel χ2 test, as appropriate. All statisti-
cal analyses were performed using Microsoft Excel (Mi-
crosoft, Redmond, WA, USA) or SAS software (SAS Insti-
tute, Cary, NC, USA).
Serum samples from 459 pregnant women and their 
neonates were obtained from June 2006 to June 2008 and 
tested for EV71 neutralizing antibody serostatus. Seroposi-
tive rates of EV71 neutralizing antibodies in these pregnant 
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ly. Seroprevalence in mothers was strongly associated with 
seroprevalence in their neonates, and neonates born to sero-
negative mothers were all seronegative (p<0.01, by McNe-
mar test). In addition, the EV71 antibody titers in seroposi-
tive neonates were highly correlated with the EV7 antibody 
titers in their mothers (R = 0.84, p<0.01) (Figure 1).
From June 2006 through June 2008, a total of 309 
neonates completed follow-up and blood collection at 6 
months of age. EV71 neutralizing antibody titers in the se-
rial serum samples from these 309 families were quantiﬁ  ed. 
The seropositive rates of EV71 neutralizing antibodies in 
the family cohorts were 65% in the mothers, 50% in the 
neonates, and 1% in the 6-month-old infants, respectively 
(Table 1). Only 4 infants 6 months of age had detectable 
EV71 antibody titers; 1 showed seroconversion on the basis 
of antibody titers measured at birth (antibody titer <8) and 
at 6 months of age (antibody titer 512). This seroconverted 
infant did not develop any enterovirus-related symptoms 
(e.g., hand, foot, and mouth disease or herpangina). Of the 
154 seropositive neonates, 3 remained seropositive and 151 
became seronegative at 6 months of age (Table 2). In the 
3 seropositive 6-month-old infants, the biological half-life 
of EV71 neutralizing antibodies was calculated as 39 and 
42 days by using cross-sectional and longitudinal analyses, 
respectively. In the 151 seronegative 6-month-old infants, 
the biological half-life of EV71 neutralizing antibody was 
calculated as 53 and 60 days by using cross-sectional and 
longitudinal analysis, respectively (Table 2).
Seroprevalence rates were predicted by making the 
assumptions that the seropositive rate of EV71 neutraliz-
ing antibodies at birth is 50%, that the GMT of these sero-
positive neonates is 21.8 (SD 0.91), and that the half-life 
of maternal EV71 neutralizing antibodies is 42 days (1.4 
months). Seroprevalence rates of EV71 neutralizing anti-
bodies during each of the ﬁ  rst 6 months of age were pre-
dicted to be 35%, 25%, 14%, 7%, 3%, and 1%, respectively 
(Figure 2). The predicted rate at 6 months of age was con-
sistent with the observed seroprevalence at 6 months of age 
in our study population.
Conclusions
We found that ≈50–60% of pregnant women had se-
rum EV71 neutralizing antibodies. These maternal EV71 
neutralizing antibodies declined to undetectable levels 
in 99% of the 6-month-old infants. Two cross-sectional 
studies found similar seropositive rates in 30–49-year-old 
adults and in 6–11-month-old infants before the 1998 epi-
demic in Taiwan (10,11). In Singapore, a cross-sectional 
study found that 44% of 70 neonates had EV71 neutralizing 
antibodies in cord blood samples, but none of 52 infants 
1–11 months old was seropositive (13).
Studies estimating the biologic half-life of EV71 ma-
ternal antibodies appear to be new. Theoretically, longitu-
dinal analysis is more reliable and has narrower conﬁ  dence 
intervals than cross-sectional analysis (1). Although only 
3 infants had detectable antibody titers at 6 months of age, 
our study estimates the biological half-life of EV71 mater-
nal antibodies to be 42 days, similar to the half-lives of an-
tibodies to other pathogens calculated by using longitudinal 
analysis (1; M.-S. Lee, unpub. data).
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Figure 1. Scatter plot and correlation of enterovirus 71 neutralizing 
antibody titers (natural logarithm transformation) in 154 pairs of 
serum samples collected from seropositive neonates and their 
mothers, Taiwan. Values on the axes are logarithmic.
Table 1. Distribution of enterovirus 71 neutralizing antibody titers in pregnant women, neonates, and 6-month-old infants in a cohort
study, Taiwan 
Antibody titer  No. (%) pregnant women, n = 307  No. (%) neonates, n = 309*  No. (%) 6-month-old infants, n = 309* 
<8 107 (34.9)  155 (50.2)  305 (99.0) 
8 79 (25.7)  44 (14.2)  3 (0.97) 
16 48 (15.6)  48 (15.5)  0
32 34 (11.1)  24 (7.8)  0
64 24 (7.8)  29 (9.4)  0
128 13 (4.2)  6 (1.9)  0
256 1 (0.3)  3 (1.0)  0
512 1 (0.3)  0 1 (0.32) 
*Two mothers delivered twins. Enterovirus 71 Antibodies in Infants, Taiwan
Our prospective serologic study in northern Taiwan 
showed no seroconversion in young infants during 2007 
and only 1 seroconversion during the ﬁ  rst half of 2008. 
Based on the national enterovirus surveillance system, 
EV71 isolations were very low in 2006 and 2007 (14,15), 
ﬁ  ndings consistent with our study.
A national program for developing EV71 vaccines 
was initiated in Taiwan in 2007. To improve vaccine de-
velopment, the target population (those at high risk) needs 
to be identiﬁ  ed. Several studies have shown that infants 
6–11 months of age in Taiwan have the highest risk for se-
vere EV71 infection and for death caused by this infection 
(8–10). Our serologic study found that 99% of 6-month-old 
infants have undetectable maternal EV71 neutralizing an-
tibodies. Consequently, EV71 vaccines being developed in 
Taiwan should target infants <6 months of age.
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Figure 2. Predicted seroprevalences of maternal enterovirus 71 
(EV71) neutralizing antibodies (antibody titer >8) in infants <6 
months of age, Taiwan. Predictions are based on assumptions that 
1) the seroprevalence in neonates is 50%, 2) the geometric mean 
titer (SD after natural logarithm transformation) in the seropositive 
neonates is 22 (0.91), and 3) the half-life of maternal EV71 
neutralizing antibodies in young infants is 42 days.
Table 2. Biological half-life of maternal enterovirus 71 neutralizing antibodies in 154 seropositive neonates, determined by cross-
sectional and longitudinal analyses, Taiwan* 
Antibody titers at 6 mo of age  No. GMT at birth (SD†)  GMT at 6 mo 
Cross-sectional mean 
half-life‡
Longitudinal mean 
half-life§
Detectable 3 203 8 39 42
Undetectable 151 21 2 53 60
Total 154 22 (0.91) 2 53 60
*GMT, geometric mean titer. 
†After natural logarithm transformation. 
‡Calculated on the basis of the GMT at birth and 6 months of age. For comparison, half-life is reported in days, assuming that1 month is equal to 30 days.
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